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Another case of acute cardiopulmonary
toxicity with cord blood infusion: is dextran
the culprit?_3424 207..211
Infusion-related adverse reactions associated with cord
blood (CB) transplants are considered to be less frequent
and less severe when compared to cryopreserved marrow
or peripheral blood stem cells.1 The true incidence of
these reactions is unknown, although it is reported that
30% to 60% of CB recipients are affected by infusion reac-
tions.1,2 Recently, there have been six published reports
of severe, life-threatening cardiopulmonary reactions
associated with CB infusions (Table 1).3,4 A review by
the National Marrow Donor Program (NMDP) and the
Food and Drug Administration (FDA) of 13 serious
CB-associated infusion reactions events showed that the
majority of cases (92%; 12/13) involved infusion of at least
one red blood cell (RBC)-replete CB unit.3 As a conse-
quence, the NMDP and FDA provided recommendations
for thawing and washing RBC-replete CB units.3We report
a case of a seventh cardiopulmonary reaction associated
with the infusion of a RBC-depleted, CB unit diluted with
human serum albumin (HSA)-dextran 40.2
The patient was a 16-year-old, 46-kg, group O Cauca-
sian female with acute biphenotypic leukemia. As part
of a clinical trial, the patient was randomly assigned to
receive a five of six HLA-matched, double-CB transplant
(Table 1). Both CB units were RBC-depleted and cryopre-
served in a solution containing 10% dimethyl sulfoxide
DMSO and 10% dextran 40. After being thawed, both CB
units were diluted 1:3 with 5% HSA-8% dextran 40 solu-
tion, for a combined final infusion volume of 411 mL and
less than 3%DMSOper unit. The total transplant dose was
2.6 ¥ 105 CD34/kg and 5.7 ¥ 107 total nucleated cells/kg
recipient weight.
The patient was medicated before transfusion with
acetaminophen, diphenhydramine, hydrocortisone, and
mannitol per institutional clinical practice guidelines. Less
than 5 minutes after starting the first CB unit, the patient
experienced a severe anaphylactic reaction characterized
by nausea, vomiting, dyspnea, wheezing, chest tightness,
tachycardia, and tachypnea.The infusionwas immediately
stopped and the patient was treated with hydrocortisone,
diphenhydramine, lorazepam, ipratropium, and albuterol
and placed on 4 L of oxygen by nasal cannula. After 10
minutes, the patient’s symptoms improved and the infu-
sion of CB Unit 1 was slowly restarted and subsequently
completed within 60minutes. After additional pretransfu-
sion medication, the patient received the second CB unit
over 60 minutes. The second infusion was uneventful
except for hypertension and a few hives 2 hours postinfu-
sion. Both were successfully treated with additional anti-
histamine and antihypertensive medications.
Diagnostic studies at the time of the infusion reaction
showed a prolonged QTc (baseline, 0.416-0.514 sec) and
elevated troponin (baseline, <0.01-1.7 ng/mL) and
B-type natriuretic peptide (baseline, 110-592 pg/mL). An
echocardiogram revealed regional hypokinesis of the
basal half of the posterior two-thirds of the septum, with
overall mildly depressed left ventricular systolic function.
The patient had no evidence of electrolyte abnormalities,
renal insufficiency, intravascular hemolysis, or acute pul-
monary changes. Pertinent EKG and laboratory studies
returned to baseline within 48 hours and were attributed
to transient myocardial ischemia.
Our patient’s symptoms were consistent with a
severe, anaphylactic reaction.We believe that the reaction
was precipitated by dextran 40. Acute, severe reactions to
dextran 40 have a reported incidence of 1 in 2000 and can
be associated with cardiac ischemia and pulmonary and
renal injury.4,5 It is noteworthy that the majority (six of
seven) of cardiopulmonary infusion reactions reported to
date were associated with CB units frozen and/or diluted
in HSA-dextran. As observed by Ma and colleagues4
reports of severe CB infusion reactions “coincide with the
introduction of dextran in cryopreservation” and include
more recent protocols for dilution or washing CB products
in HSA-dextran.2 Ongoing investigations into severe CB
reactions should include the potential role of dextran in
such reactions, as well as possible prophylaxis with
dextran-1, a hapten known to significantly decrease the
risk of dextran reactions.4,5
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Isoimmune neonatal neutropenia in a North
African newborn due to anti-Fcg RIIIb_3434 208..212
HumanFcgRIIIb (FcgRIIIb; CD16) is a low-affinity Fc recep-
tor for immunoglobulin (Ig)G1 and IgG3, constitutively
expressedwith ahighdensity (100,000 to 400,000 copies per
cell), only by granulopoietic cells.1 The human neutrophil
antigens HNA-1a, HNA-1b, and HNA-1c, encoded by the
FcgRIIIb gene, are polymorphic forms of this receptor.2
Alloantibodies directed against these antigens can be
responsible for neonatal alloimmune neutropenia,
transfusion-related acute lung injury, and autoimmune
neutropenia. Few people (approx. 1 of 1000 individuals of
European origin) lack the FcgRIIIb gene and present the
HNA-1 null phenotype (FcgRIIIb deficiency).3 During preg-
nancy, women lacking this gene, and subsequently the
protein, can produce CD16 isoantibodies able to cross the
placenta and cause transient isoimmune neonatal neutro-
penia (INN).4,5
We report a case of INN due to an anti-FcgRIIIb in a
motherwithFcgRIIIbdeficiency.A25-year-oldmother from
North Africa prematurely delivered a female newborn at 33
weeks of gestation (bodyweight, 2300 g), due to early labor.
The two previous pregnancies were free of complications
and the newborns were healthy. In this case, systematic
newborn blood screening showed severe neutropenia
(200 ¥ 106 neutrophils/L) and hypocalcemia (1.94 mmol/L)
on the first day of life with no other clinical or biologic
abnormalities. No complication was observed in the child
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and,withoutanytreatment, theneutrophil countspontane-
ously increased to 600 ¥ 106/L on Day 18 and 1800 ¥ 106/L
after 1 month, when she was discharged from the hospital.
Neonatalalloimmuneneutropeniawassuspectedandlabo-
ratory tests were performed on maternal and newborn
blood samples obtained immediately after delivery.
IgG anti-granulocyte antibodies were detected in
maternal serum by means of a strongly positive granulo-
cyte immunofluorescence test (GIFT), but not by the
granulocyte agglutination test (GAT) even after sera
dilution (to 1/2 to 1/512). A high level of anti-CD16 was
identified by monoclonal antibody immobilization of
granulocyte antigen assay. Granulocyte antibodies were
also found in the newborn by GIFT. Maternal neutrophils
were typed as CD16 negative with the GAT using poly-
clonal antibodies. HNA-1 genotyping was performed by
polymerase chain reaction-sequence specific primers
(PCR-SSP). The newborn was found negative for HNA-1a
andHNA-1c, but positive forHNA-1b, whereas themother
was negative for HNA-1a, -1b, and -1c, consistent with an
FcgRIIIb deficiency (Fig. 1).
Our observation confirms the risk for a mother with
FcgRIIIb deficiency to produce CD16 isoantibodies, which
can be responsible for INN. To the best of our knowledge,
no FcgRIIIb deficiency has been reported in people origi-
nating from North Africa. It is known that the HNA-1 null
phenotype is more frequent in Africans (1%-2%) than in
Caucasians (0.15%) and nearly absent in Asians and Amer-
indians.6 Interestingly, this rare null phenotype has been
found in 0.8% of Spanish blood donors, which may be
related to their berberian origin.7 Paradoxically, as in our
patient, most of the FcgRIIIb-deficient individuals do
not suffer from repeated infections or autoimmune or
immune complex diseases, while this receptor contrib-
utes to the phagocytosis of opsonized microorganisms
and the clearance of immune complex from the circula-
tion.8 Further investigations are required to explain the
absence of immune consequences in individuals carrying
this rare phenotype.
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Syncope after whole blood donation: factors
associated with increased donor injury_3439 210..214
Syncope occurs in 0.13% (American Red Cross [ARC]
whole-blood donation database, unpublished data, July 1,
2005-June30, 2010) to0.27%1,2 of all allogeneicwholeblood
donations and in approximately 4% to 5% (sameARCdata-
base) of vasovagal reactions. Sixty percent1 of syncopal
reactions occur after the donor leaves the donor bed, with
10% to 12%1,3 of reactions occurring after the donor leaves
thedonation site. Syncopeafter donors standup is an issue
because approximately 4% to9%ofdonorswho fall sustain
an injury (same ARC database).1 The donor injury rate for
allogeneic whole blood donations is 0.011% (same ARC
database) to 0.014%.1 Overwhelmingly, the injuries are
minor, but there can be severe injuries such as fractures,
lacerations, and closed head injuries.
It seems intuitive that the risk of donor injury would
be the same for all donors who progress to syncope. This
hypothesis was tested by analyzing 30.2million allogeneic
whole blood donations to the American Red Cross over a
5-year period (same ARC database). The syncope and
donor injury rates at the collection sites were evaluated.
The overall donor syncope and injury rates were
0.13% (39,392/30,190,815) and 0.011% (3462/30,190,815),
respectively, and a donor injury occurred in 8.8% of the
syncopal episodes.
The proportion of syncopal episodes associated with
donor injuries was evaluated by age interval for donations
by all donors, first-time female donors, repeat female
donors, first-time male donors, and repeat male donors
(Table 1). For each of these donor groups, the baseline
interval was defined as the interval, among all intervals
with at least 40 donor injuries, that had the lowest propor-
tion. The ratio of the proportion for each interval to the
proportion for the baseline—that is, the relative risk—was
calculated. The proportions and relative risks were also
evaluated for all donors grouped by sex and donation
status (first-time vs. repeat donation).
Table 1 shows that for all donations, the proportion of
syncopal episodes associated with injuries is highest in
16-year-old donors, decreases with increasing age, and
begins to plateau in the 29- to 42-year-old age group. Rela-
tive risks are increased in 16-, 17-, 18-, and 19-year-olds by
125, 96, 72, and 39%, respectively. The same pattern is
observed in first-time and repeat female donors and also
in first-time male donors but not in repeat male donors.
Donor injury rates after syncope were 17% higher in
females (9.3% [2222/23,855]) than in males (8.0% [1240/
15,537]; 95% confidence interval [CI], 1.09-1.25) and 12%
higher in first-time donors (9.3% [1887/20,354]) than in
repeat donors (8.3% [1575/19,038]; 95% CI, 1.05-1.19).
These findings show that donor injury rates after
syncope are greatly increased in very young donors and
also increased, but to amuch lesser degree, in females and
first-time donors. A study of the character of syncopal
reactions in very young donors and older donors might
explain why the rates of donor injuries after syncope differ
with age. A better understanding of syncope could poten-
tially help us to improve safety for donors.
CONFLICT OF INTEREST
None.
Bruce Newman, MD
e-mail: newmanb@usa.redcross.org
American Red Cross Southeastern Michigan Blood
Services Region
Detroit, MI
Barry Siegfried, MD
American Red Cross Great Lakes Blood Services Region
Lansing, MI
TABLE 1. Relationship between donor syncope and donor injury: influence of age, sex, and donation history
Age group
(years)
All donors Injury/syncope (%)
Incidence of
syncope (per 10,000)
Incidence of
injury (per 10,000) Injury/syncope (%)
Females Males
First-time Repeat First-time Repeat
16 48.1 6.5 13.6* 13.5* 14.1* 14.4* 8.7
17 43.5 5.2 11.9* 13.1* 11.4* 10.4* 10.9*
18 35.6 3.7 10.4* 11.1* 12.1* 8.7* 8.2
19 32.2 2.7 8.4* 7.6* 10.3* 6.3 8.2
20-22 24.5 1.8 7.5* 5.9 9.1* 7.7* 6.8
23-28 17.0 1.3 7.9* 7.8* 8.0* 7.4* 8.5
29-42 9.3 0.6 6.2 6.2 7.0 4.4† 6.8†
43-57 5.2 0.3 6.0† 5.1† 6.0† 5.5 7.0
58-96 4.7 0.3 6.1 5.0 6.8 3.3 5.8
Total 13.0 1.1 8.8 9.9 8.7 8.3 7.6
* Risk is greater than baseline’s risk (lower 95% confidence limit for relative risk >1.0).
† Baseline for group.
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